EUVIMEDEUVIMED entdecken
Crossref

Target Trial Emulation of SARS-CoV-2 Infection Versus No Infection and Risk of Post–COVID-19 Conditions in the Omicron Variant Versus Prior Eras

George N Ioannou iD, Kristin Berry, Nallakkandi Rajeevan, Yuli Li, Lei Yan iD, Yuan Huang, David Bui iD, Denise M Hynes iD, Mazhgan Rowneki, Alex Hickok, Meike Niederhausen, Troy A Shahoumian und 17 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von George N Ioannou und 28 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit nennt 38 Literaturangaben. Gefördert von: HSRD VA, CSP VA, US Department of Veterans Affairs..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronavirus disease 2019 (COVID-19) has been linked to the development of post–COVID-19 conditions (PCCs). We investigated whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection increases the risk of selected PCCs or death up to 1 year after infection, separately in the wild-type (WT), Alpha-transition, Delta, and Omicron eras and by vaccination status.

Methods

We used health records of the Veterans Health Administration to emulate a hypothetical target trial of SARS-CoV-2 infection versus no infection. Veterans who tested positive for SARS-CoV-2 between March 2020 and April 2022 (n = 430 160) were matched 1:1 to veterans who had not tested positive for SARS-CoV-2. All-cause mortality and cumulative incidence of 32 potential PCCs were ascertained at 31–180 and 181–365 days after infection or matched index date.

Results

From 31 to 180 days, the cumulative incidence of death and all organ-level PCCs was greater in infected versus uninfected participants, with cumulative incidence differences lower in the Omicron than in the WT era and lower in vaccinated than in unvaccinated persons. In the Omicron era, the cumulative incidence of death and most PCCs from day 181–365 were higher in infected than in uninfected participants only among unvaccinated but not among vaccinated persons.

Conclusions

Excess burden of PCCs and mortality persisted 31–180 days after infection in the Omicron era, albeit at a lower level than in the WT and Delta eras. Excess burden of mortality and most PCCs was much lower 181–365 days after infection and was observed in the Omicron era only among unvaccinated persons, suggesting a protective effect of vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2HumansMaleFemaleMiddle AgedAgedUnited StatesCOVID-19 VaccinesIncidenceAdultVeteransVaccination

Stichwörter der Autor:innen

COVID-19Omicron variantlong COVIDpost-COVID conditionspostacute sequelae of COVID-19 (PASC)

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.
  • Divisions of Gastroenterology, Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, Washington, USA.
  • Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center (CSP-CERC), Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA.
  • Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, Connecticut, USA.
  • Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
  • Research and Development, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.

ORCID-Profile: George N Ioannou, Lei Yan, David Bui, Denise M Hynes, Edward J Boyko, Anna Korpak, Thomas F Osborne, Elizabeth M Viglianti, Kristina L Bajema

Förderung

  • HSRD VA
  • CSP VA
  • US Department of Veterans Affairs.
  • Cooperative Studies Program
  • Health Services Research & Development

Zitieren

APA

Ioannou, G. N., Berry, K., Rajeevan, N., Li, Y., Yan, L., Huang, Y., Bui, D., Hynes, D. M., Rowneki, M., Hickok, A., Niederhausen, M., Shahoumian, T. A., Bohnert, A., Boyko, E. J., Korpak, A., Fox, A., Baraff, A., Iwashyna, T. J., Maciejewski, M. L., …, & Bajema, K. L. (2025). Target Trial Emulation of SARS-CoV-2 Infection Versus No Infection and Risk of Post–COVID-19 Conditions in the Omicron Variant Versus Prior Eras. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf087

Vancouver

Ioannou GN, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, et al. Target Trial Emulation of SARS-CoV-2 Infection Versus No Infection and Risk of Post–COVID-19 Conditions in the Omicron Variant Versus Prior Eras. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf087

BibTeX
@article{Ioannou2025,
  author = {Ioannou, George N and Berry, Kristin and Rajeevan, Nallakkandi and Li, Yuli and Yan, Lei and Huang, Yuan and Bui, David and Hynes, Denise M and Rowneki, Mazhgan and Hickok, Alex and Niederhausen, Meike and Shahoumian, Troy A and Bohnert, Amy and Boyko, Edward J and Korpak, Anna and Fox, Alexandra and Baraff, Aaron and Iwashyna, Theodore J and Maciejewski, Matthew L and Smith, Valerie A and Berkowitz, Theodore S Z and Pura, John A and Hebert, Paul and Wong, Edwin S and O'Hare, Ann M and Osborne, Thomas F and Viglianti, Elizabeth M and Aslan, Mihaela and Bajema, Kristina L},
  title = {Target Trial Emulation of SARS-CoV-2 Infection Versus No Infection and Risk of Post–COVID-19 Conditions in the Omicron Variant Versus Prior Eras},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf087}
}
Kostenlos starten →